In a 76-year-old patient with hypercalcemia, chronic kidney disease, normal parathyroid hormone level, and faint IgM kappa and IgG lambda monoclonal proteins, what is the next step in management?

Next Step: Comprehensive Workup for Suspected Multiple Myeloma

The next step is to perform serum protein electrophoresis (SPEP) with immunofixation, serum free light chain assay, 24-hour urine protein electrophoresis with immunofixation, complete blood count, comprehensive metabolic panel, and skeletal survey to evaluate for multiple myeloma as the cause of hypercalcemia. 1

Rationale for This Approach

Why Multiple Myeloma is the Primary Concern

• The presence of multiple monoclonal bands (faint IgM kappa and two faint IgG lambda bands) in a 76-year-old patient with hypercalcemia, CKD, and normal PTH strongly suggests a plasma cell dyscrasia, most likely multiple myeloma 1

• Normal PTH in the setting of hypercalcemia indicates PTH-independent hypercalcemia, effectively ruling out primary hyperparathyroidism and pointing toward malignancy or other non-PTH-mediated causes 2, 3

• Multiple myeloma is one of the most common cancers associated with hypercalcemia of malignancy, and hypercalcemia in myeloma is defined as corrected serum calcium exceeding 11.5 mg/dL attributable to the plasma cell disorder with heightened bone resorption 1

Essential Diagnostic Tests

The complete workup should include:

• Serum protein electrophoresis (SPEP) with immunofixation to quantify and characterize the monoclonal proteins 4

• Serum free light chain assay to assess kappa/lambda ratio, which is critical for diagnosing light chain myeloma and monitoring disease 4

• 24-hour urine protein electrophoresis with immunofixation to detect Bence Jones proteins 4

• Complete blood count to evaluate for anemia, which is characteristic of malignancy-associated hypercalcemia but not hyperparathyroidism 2

• Comprehensive metabolic panel to assess renal function and calcium levels, and to check for absence of hyperchloremic metabolic acidosis (which would suggest hyperparathyroidism rather than malignancy) 2

• Skeletal survey (not bone scan) to identify lytic bone lesions characteristic of multiple myeloma 1

• Bone marrow biopsy with aspirate if initial testing supports myeloma diagnosis, to quantify plasma cell percentage 4

Important Diagnostic Pitfalls to Avoid

• Do not order PTHrP (parathyroid hormone-related protein) C-terminal assay in this CKD patient, as C-terminal PTHrP accumulates in kidney disease and can be falsely elevated in normocalcemic CKD patients without malignancy 5

• If PTHrP testing is deemed necessary (though less likely given the monoclonal proteins), specifically request the N-terminal PTHrP assay, which is the appropriate test for patients with advanced kidney disease 5

• The coexistence of hyperparathyroidism and multiple myeloma is rare but possible; however, the normal PTH makes primary hyperparathyroidism unlikely as the cause of hypercalcemia 4

Concurrent Management Considerations

While completing the diagnostic workup, assess the severity of hypercalcemia to determine if immediate treatment is needed:

• If serum calcium is >14 mg/dL (severe hypercalcemia): Initiate treatment with IV hydration and IV bisphosphonate (zoledronic acid or pamidronate) or denosumab, with consideration of adding calcitonin for the first 48-72 hours 6, 3

• If serum calcium is 12-14 mg/dL (moderate hypercalcemia): Initiate IV hydration and IV bisphosphonate or denosumab 6

• If serum calcium is <12 mg/dL (mild hypercalcemia): May observe while completing workup, though treatment can be considered if symptomatic 3

• Given the patient's CKD, denosumab may be preferred over bisphosphonates if severe hypercalcemia requires treatment, as bisphosphonates require dose adjustment in renal impairment 6, 7